Missed dose: difference between revisions
Diff·revision 12 → 13·06:22, 14 May 2025
Difference between revision 12 and revision 13 of Missed dose. 5 lines changed; the page grew by 582 bytes.
| Revision 12 — 05:09, 18 Apr 2025 GMP_Gita (talk) serial comma per PP:MOS 4,407 bytes ±0 | Revision 13 — 06:22, 14 May 2025 ProglucagonPia (talk) convert the conversion list to a table so the three syringe scales align 4,989 bytes +582 | ||
|---|---|---|---|
| 34 | Doubling a dose to compensate for an omission is not what any labelling in this class directs, and the pharmacokinetics do not support it: a double dose produces a peak exposure outside the studied range, which is where the dose-related adverse effects concentrate.{{r|knudsen2019}} | 34 | Doubling a dose to compensate for an omission is not what any labelling in this class directs, and the pharmacokinetics do not support it: a double dose produces a peak exposure outside the studied range, which is where the dose-related adverse effects concentrate.{{r|knudsen2019}} |
| 35 | 35 | ||
| + | 36 | == Practical corollaries == | |
| + | 37 | The main practical corollary of a long half-life is that the effect of any change — starting, stopping, escalating, or missing — is expressed slowly. A dose increase is not fully expressed for four to five weeks with a weekly agent, and neither is a decrease.{{r|knudsen2019}} | |
| + | 38 | ||
| + | 39 | That has a symmetrical consequence for interpreting adverse effects. An effect appearing three days after a dose change may be attributable to it; one appearing three weeks later, at a time when concentrations are still rising towards a new steady state, may equally be. | |
| + | 40 | ||
| 36 | == References == | 41 | == References == |
| 37 | {{reflist}} | 42 | {{reflist}} |